In 2017, Chang et al. treated the human cervical cancer HeLa cells with the PPARγ agonists ciglitazone and troglitazone, which, in higher doses, activated caspase-3 and PARP cleavage, thereby inducing apoptotic cell death in a time- and dose-dependent way [57]. The gene discussed is PPARG; the disease is cervical carcinoma.